Timing of ADC drug for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman aged 18 to 75 years old.
- Have advanced breast cancer that is HER2-negative (a type that does not have too much HER2 protein).
- Your cancer has gotten worse after at least one round of chemotherapy for advanced disease.
- If your cancer is hormone receptor-positive, you must have already tried at least one hormone therapy.
- Be in good enough health to carry out daily activities (ECOG performance status less than 2).
- Have adequate kidney, liver, and blood cell counts based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a sequence of antibody-drug conjugates (ADCs) for advanced breast cancer that is hormone receptor positive and HER2 negative, after standard therapy has stopped working. It aims to find a new treatment option for people whose disease has progressed on a CDK4/6 inhibitor and endocrine therapy.
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
This trial is for people with HER2-low breast cancer who have already received two or more antibody-drug conjugates (ADCs) in a row. Researchers want to find the best order to use these targeted therapies to get the most benefit.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
Hear when a new Breast Cancer Females trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.